rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PDSB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PDS Biotechnology: Q3 Earnings Snapshot
      Nov 13Yahoo FinanceDTILPDSB
      PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
      Nov 4Yahoo FinancePDSB
      B.Riley raises PDS Biotechnology stock price target on trial data
      Oct 29Investing.comPDSBRILYRILYGRILYLRILYNRILYTRILYZ
      PDS Biotechnology appoints three directors to board
      Oct 20Investing.comPDSB
      PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17
      Oct 17Seeking AlphaPDSB
      PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
      Oct 16Yahoo FinancePDSB
      PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
      Oct 14Yahoo FinancePDSB
      12 Health Care Stocks Moving In Friday's Intraday Session - Quantum-Si (NASDAQ:QSI), Nautilus Biotechnolo
      Oct 9BenzingaPDSBQSI
      12 Health Care Stocks Moving In Monday's Intraday Session - HeartBeam (NASDAQ:BEAT), PDS Biotechnology (N

      Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology (NASDAQ:PDSB) shares moved

      Oct 5BenzingaBEATPDSB
      PDS Biotech reports 39.3-month survival data for HPV16 therapy
      Sep 22Investing.comPDSB
      PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

      The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair...

      Sep 18Yahoo FinancePDSB
      PDS Biotech Stock Surges Tuesday: What's Driving the Action?
      Sep 15BenzingaPDSB
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Sep 15BenzingaPDSB
      PDS Biotechnology closes $11.3M private placement led by Soon-Shiong
      Sep 14Investing.comPDSB
      PDS Biotechnology Reports Initial Closing of Private Financing

      PDS Biotechnology (PDSB) said Monday it has raised about $11.3 million from an initial closing of a

      Sep 14Yahoo FinancePDSB
      Dow Tumbles 450 Points; US Small Business Sentiment Declines In August
      Sep 8BenzingaPDSB
      PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise

      PDS Biotechnology (PDSB) said Tuesday it raised up to about $22.6 million in equity funding through

      Sep 8Yahoo FinancePDSB
      PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
      Sep 8Yahoo FinancePDSB
      PDS Biotech raises up to $22.55M led by Nant Capital
      Sep 8Investing.comPDSB
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Tipranks Press Release.

      Aug 27The Globe and MailPDSBSPRB

      This is the newest page. Registered accounts read further back.